In head and neck squamous cell carcinoma (HNSCC), studies found that the combination of the epidermal growth factor receptor (EGFR) inhibitor cetuximab and the PARP-1 inhibitor olaparib produces significant synergistic radiosensitizing effects. The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.